Linked Life Data

19825907

Source:http://linkedlifedata.com/resource/pubmed/id/19825907

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
12
pubmed:dateCreated
2010-12-8
pubmed:abstractText
In the present study, we investigated the effects of sertraline on plasma levels of 3-methoxy-4-hydroxyphenylglycol (MHPG), homovanillic acid (HVA), and serum brain-derived neurotrophic factor (BDNF) levels in 59 depressed patients treated with sertraline. We also examined the relationship between the dynamics of the catecholamine metabolites, BDNF, serotonin transporter-linked polymorphic region (5-HTTLPR) gene polymorphism (long and short alleles), and the clinical response to sertraline. The extent of clinical improvement was evaluated using the 17-item Hamilton Rating Scale for Depression (Ham-D) before and 8 weeks after treatment with sertraline. Responders were defined as showing at least a 50% decrease in the Ham-D score. Baseline plasma HVA levels of responders to sertraline treatment were significantly lower than those of non-responders (p = 0.02). In addition, a positive correlation was identified between changes in plasma HVA levels and the rate of response to sertraline treatment (p = 0.001). A trend toward higher baseline serum BDNF levels was found in responders compared with non-responders (p = 0.095). In addition, serum BDNF levels were slightly increased (not significant) in responders (p = 0.058), but not in non-responders. Responders had a higher short-allele genotype frequency in the 5-HTTLPR for the promoter region than did non-responders (p = 0.037). These results suggest that pre-treatment plasma HVA levels and the 5-HTTLPR genotype for the promoter might be associated with a response to sertraline.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
1461-7285
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
24
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1764-71
pubmed:meshHeading
pubmed-meshheading:19825907-Adult, pubmed-meshheading:19825907-Aged, pubmed-meshheading:19825907-Aged, 80 and over, pubmed-meshheading:19825907-Alleles, pubmed-meshheading:19825907-Brain-Derived Neurotrophic Factor, pubmed-meshheading:19825907-Depressive Disorder, Major, pubmed-meshheading:19825907-Female, pubmed-meshheading:19825907-Homovanillic Acid, pubmed-meshheading:19825907-Humans, pubmed-meshheading:19825907-Male, pubmed-meshheading:19825907-Methoxyhydroxyphenylglycol, pubmed-meshheading:19825907-Middle Aged, pubmed-meshheading:19825907-Polymorphism, Genetic, pubmed-meshheading:19825907-Promoter Regions, Genetic, pubmed-meshheading:19825907-Serotonin Plasma Membrane Transport Proteins, pubmed-meshheading:19825907-Serotonin Uptake Inhibitors, pubmed-meshheading:19825907-Sertraline, pubmed-meshheading:19825907-Severity of Illness Index, pubmed-meshheading:19825907-Treatment Outcome, pubmed-meshheading:19825907-Young Adult
pubmed:year
2010
pubmed:articleTitle
Predictive factors for responding to sertraline treatment: views from plasma catecholamine metabolites and serotonin transporter polymorphism.
pubmed:affiliation
Department of Psychiatry, School of Medicine, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyusyu, Fukuoka, Japan. wakako-u@med.uoeh-u.ac.jp
pubmed:publicationType
Journal Article, Clinical Trial, Research Support, Non-U.S. Gov't